Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease
Objective: Characterize the relationship between foslevodopa/foscarbidopa infusion rate and infusion site reaction (ISR) score in patients with Parkinson’s disease (PD) Background: As PD progresses, motor…Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients
Objective: To characterize safety/tolerability and pharmacokinetics (PK) of levodopa (LD) and carbidopa (CD) after delivery of foslevodopa/foscarbidopa in Parkinson’s disease (PD) patients at 4 different…The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model
Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients
Objective: To assess safety, tolerability, and central effects of L-Dihydroxyphenylserine (L-DOPS), in Parkinson’s disease (PD) patients treated with DOPA decarboxylase inhibition. Background: Norepinephrine (NE) is…Restoring AADC enzyme synthesis in AADC deficiency: MRI-Guided Delivery of AAV2-hAADC Gene Therapy to the Midbrain
Objective: Evaluate the safety and efficacy of real-time MR-guided delivery of adeno-associated virus serotype 2 (AAV2)-hAADC delivery to the SNc and VTA for the treatment…Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01
Objective: To describe changes over the first year in disease severity and activities of daily living using modified Hoehn and Yahr (mH&Y) stage and UPDRS…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa
Objective: To characterize the peripheral pharmacokinetics and CNS metabolism of levodopa during continuous subcutaneous delivery of solubilized carbidopa. Background: Although many commercial levodopa formulations include…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.